Skip to main content

Advertisement

Table 2 Multivariate analysis of NLR determined by ROC for patients with advanced NPC

From: Prognostic value of neutrophil-to-lymphocyte ratio in advanced nasopharyngeal carcinoma: a large institution-based cohort study from an endemic area

Endpoint Variable HR 95% CI for HR P value
OS
  Age (≤ 45 vs. >  45) 1.69 1.29–2.22 < 0.001
  Sex (Male vs. Female) 1.30 0.90–1.87 0.163
  Smoking history (No vs. Yes) 1.11 0.83–1.49 0.492
  T stage (T1–2 vs. T3–4) 1.34 0.98–1.85 0.071
  N stage (N0–1 vs. N2–3) 2.86 2.19–3.73 < 0.001
  NLR (≤ 2.50 vs. >  2.50) 1.72 1.31–2.24 < 0.001
  Treatment (RT alone vs CCRT) 1.43 0.82–2.50 0.213
  Treatment (RT alone vs NACT+CCRT) 1.23 0.70–2.14 0.472
DMFS
  Sex (Male vs. Female) 1.34 0.95–1.90 0.097
  N stage (N0–1 vs. N2–3) 3.50 2.65–4.63 < 0.001
  NLR (≤ 2.50 vs. >  2.50) 1.45 1.10–1.92 0.009
LRFS
  Age (≤ 45 vs. >  45) 1.40 1.02–1.92 0.035
  N stage (N0–1 vs. N2–3) 1.35 0.97–1.88 0.077
PFS
  Age (≤ 45 vs. >  45) 1.44 1.16–1.79 0.001
  Family history (No vs. Yes) 1.17 0.91–1.50 0.213
  Smoking history (No vs. Yes) 1.12 0.90–1.39 0.323
  T stage (T1–2 vs. T3–4) 1.27 0.99–1.62 0.063
  N stage (N0–1 vs. N2–3) 2.25 1.81–2.79 < 0.001
  NLR (≤ 2.50 vs. >  2.50) 1.29 1.04–1.59 0.021
  1. Abbreviation: OS overall survival, DMFS distant metastasis-free survival, LRFS locoregional relapse-free survival, PFS progression-free survival, RT radiotherapy, CCRT concurrent chemoradiotherapy, NACT neoadjuvant chemotherapy, NLR neutrophil-to-lymphocyte ratio, HR rate ratio, CI confidence interval